Orthofix International NV (NASDAQ:OFIX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.
According to Zacks, “Orthofix International N.V. is a leading provider of high-value, minimally invasive medical devices for the orthopaedic and trauma markets. Orthofix is well positioned to expand its focus and capitalise on the growing medical acceptance of high technology in orthopaedic treatment and spine repair. The company sells its diverse product line in different countries through its subsidiaries and distribution agreements with leading orthopaedic companies, including Sulzer Medica Group, Sofamor Danek Group, Kendall Healthcare Products and B. Braun. (PRESS RELEASE) “
Separately, TheStreet lowered shares of Orthofix International NV from a “buy” rating to a “hold” rating in a research report on Wednesday, August 3rd.
Shares of Orthofix International NV (NASDAQ:OFIX) opened at 40.54 on Tuesday. Orthofix International NV has a 52-week low of $32.25 and a 52-week high of $48.25. The company’s 50-day moving average is $43.70 and its 200 day moving average is $43.83. The firm’s market capitalization is $734.75 million.
Orthofix International NV (NASDAQ:OFIX) last issued its earnings results on Monday, August 1st. The medical device company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.33 by $0.08. The company had revenue of $104.10 million for the quarter, compared to analyst estimates of $102.40 million. Orthofix International NV had a negative net margin of 0.37% and a positive return on equity of 8.50%. The business’s revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.36 EPS. Equities analysts expect that Orthofix International NV will post $1.41 earnings per share for the current fiscal year.
In other Orthofix International NV news, insider Michael Finegan sold 25,000 shares of the business’s stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $45.16, for a total transaction of $1,129,000.00. Following the sale, the insider now directly owns 51,670 shares in the company, valued at approximately $2,333,417.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.10% of the company’s stock.
Several large investors have recently added to or reduced their stakes in OFIX. Teacher Retirement System of Texas raised its stake in Orthofix International NV by 14.1% in the second quarter. Teacher Retirement System of Texas now owns 2,646 shares of the medical device company’s stock valued at $112,000 after buying an additional 327 shares in the last quarter. BlackRock Inc. raised its position in Orthofix International NV by 114.0% in the second quarter. BlackRock Inc. now owns 3,139 shares of the medical device company’s stock worth $133,000 after buying an additional 1,672 shares during the period. BNP Paribas Arbitrage SA raised its position in Orthofix International NV by 50.3% in the third quarter. BNP Paribas Arbitrage SA now owns 3,114 shares of the medical device company’s stock worth $133,000 after buying an additional 1,042 shares during the period. Globeflex Capital L P raised its position in Orthofix International NV by 11,733.3% in the second quarter. Globeflex Capital L P now owns 4,260 shares of the medical device company’s stock worth $181,000 after buying an additional 4,224 shares during the period. Finally, Citadel Advisors LLC purchased a new position in Orthofix International NV during the second quarter worth about $222,000. Institutional investors and hedge funds own 91.26% of the company’s stock.
Orthofix International NV Company Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orthofix International NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International NV and related companies with MarketBeat.com's FREE daily email newsletter.